AbCellera Biologics Inc..
ABCL.US | Research and experimental development on natural sciences and engineering
AbCellera Biologics Inc. is a biotechnology company focused on antibody discovery and development. They operate as a technology and service provider, offering an integrated platform for the discovery of therapeutic antibodies. Their services include target validation, antibody discovery, lead optimi...Show More
Better Health for All
10
AbCellera's core business is entirely devoted to health improvement through the discovery and development of therapeutic antibodies for various diseases, including infectious diseases, cancer, immune diseases, menopause treatment, and atopic dermatitis. The company does not generate revenue from products with negative health outcomes.
1
Its research focuses on diseases impacting developing countries and infants in low and middle-income countries, indicating a significant reach to vulnerable populations.
2
The company is co-investing CA$401 million over eight years, alongside CA$300 million from Canadian governments, to build drug development capabilities, which is expected to create hundreds of new high-skilled jobs in computer science, life sciences, healthcare, and manufacturing.
3
Health Canada approved clinical trials for a non-hormonal menopause treatment and a Phase 1 trial for atopic dermatitis in May 2025.
4
The company received a $2,094,770 grant in January 2022 for pneumonia and pandemic preparedness, and $4.8 million in March 2019 for research into vaccines and antibody treatments for infectious diseases.
5
Fair Money & Economic Opportunity
0
AbCellera Biologics Inc. is a biotechnology company that provides research and development services to pharmaceutical and biotechnology partners.
1
The company's business model does not involve lending, insuring, moving, or storing money for consumers, nor does it offer any financial products or services.
2
Consequently, all Key Performance Indicators related to fair money and economic opportunity, which are designed for financial institutions, are not applicable to AbCellera's operations.
Fair Pay & Worker Respect
0
For fiscal year 2024, the CEO total compensation to median employee compensation ratio was 63:1.
1
Employee reviews indicate that 60% of employees would recommend working at the company to a friend, and the overall employee rating is 3.4 out of 5 stars.
2
Employee reviews also mention the company offers "good health benefits".
3
Fair Trade & Ethical Sourcing
0
No specific, quantitative data points were found across the provided articles to assess AbCellera Biologics Inc. against any of the Fair Trade & Ethical Sourcing KPIs. The articles primarily focus on financial performance, business strategy, or general policy statements without providing measurable outcomes or percentages related to fair trade certifications, audit frequencies, labor incidents, supply chain traceability, remediation speed, ethical clause coverage, materials risk, or supplier diversity spend.
Honest & Fair Business
-40
AbCellera Biologics Inc. has established a confidential hotline and web form for reporting accounting, internal accounting controls, or auditing matters.
1
This hotline is mandated by the SEC.
2
However, there is no evidence provided regarding independent investigation processes for reports made through this channel.
Kind to Animals
-60
AbCellera Biologics Inc. states a commitment to conducting animal research responsibly, humanely, and ethically, and is dedicated to reducing, replacing, and refining animal use in in vivo applications, in accordance with all applicable laws and regulations.
1
However, the company does engage in animal testing for some medical analysis and clinical research, and no measurable goals or accountability for reduction are provided.
2
The company used between 25,000 and 50,000 animals in testing in 2021. AbCellera is a founding partner in Invetx and has an expanded agreement to generate therapeutic antibody candidates for animal health, with Invetx developing protein-based therapies for pets and companion animals.
3
No War, No Weapons
0
The provided articles do not contain specific, quantifiable evidence to assess AbCellera Biologics Inc. against the 'No War, No Weapons' ethical value. While the company's Code of Business Conduct and Ethics (effective November 19, 2024) states a commitment to comply with sanctions and international trade controls, and prohibits firearms or other weapons in the workplace, these are general policy statements or workplace rules rather than specific outcomes, percentages, or detailed actions related to arms contracts, dual-use technology, or peacebuilding investments.
1
No information was found regarding revenue from defense contracts, R&D in dual-use technologies, sales to embargoed regimes, or investments in peacebuilding initiatives.
2
The company's commitment to a zero-tolerance approach to modern slavery in its supply chain is noted, but this does not provide specific data for the 'procurement_humanitarian_compliance' KPI as defined by the rubric's thresholds related to military suppliers or war crimes.
3
Planet-Friendly Business
20
In 2023, AbCellera's CO2 emissions from research were 42.6 metric tons.
1
The company sourced 35% of its energy from renewable sources in 2023.
2
Water consumption in 2023 was 89,500 gallons per month, which, when calculated against the implied 2023 revenue of $231.76 million, translates to approximately 17.54 m³ per $1 million in revenue.
3
Respect for Cultures & Communities
0
AbCellera has established various ways for individuals to raise concerns, including a Confidential and Anonymous Financial Concern Hotline and additional avenues identified in its Code of Conduct.
1
No specific information is provided regarding community-specific mechanisms or the percentage of operational sites covered by these mechanisms.
2
Safe & Smart Tech
0
AbCellera states it will not sell, rent, or lease personally identifiable information to any third party for any purpose, and third parties providing support services are prohibited from using the information for their own marketing purposes.
1
Users have the right to access, rectify, and request deletion of their personal information, and can withdraw consent for data collection.
2
The company states it collects only necessary data.
3
AbCellera mentions compliance with the Data Protection Act 1998, the General Data Protection Regulation (GDPR), the British Columbia Personal Information Protection Act, HIPAA, and CCPA.
4
The company maintains an Enterprise Risk Management (ERM) program and a cybersecurity incident response plan.
5
Its Chief Legal and Compliance Officer and IT team have over 40 years of industry experience, and IT team members hold Certified Information Security Manager certifications.
6
The Audit Committee reviews the ERM process, including cybersecurity risks, at least annually.
7
Employee awareness training initiatives are in place, and the company regularly monitors and assesses its cybersecurity infrastructure with third-party consultants.
8
The company has a process to identify and assess potential risks from cybersecurity threats associated with its use of critical third-party service providers.
9
Cybersecurity incidents are escalated based on defined incident severity criteria to management.
10
The company mentions necessary cookies for secure log-in.
11
Regular vulnerability scanning and penetration testing are required under HIPAA.
12
The company states that cybersecurity incidents have not materially affected its business, operations, or financial condition to date.
13
No specific data breaches or quantitative metrics on cybersecurity investment, training effectiveness, encryption, or AI ethics governance are provided.
Zero Waste & Sustainable Products
-40
In 2023, AbCellera Biologics Inc. replaced 22% of its single-use plastics.
1
The company also achieved a 37.5% reduction in laboratory waste in 2023.
2
Additionally, AbCellera recycled 18.3 metric tons of chemicals in 2024.
3
The company has a target to reduce laboratory waste by 50% by 2025.
4